ERBB2 and breast cancer: The PALOMA 3 study clearly showed that adding palbociclib to fulvestrant resulted in substantially longer progression-free survival than fulvestrant alone in patients with advanced HR-positive and HER2-negative breast cancer that had progressed during prior endocrine therapy, regardless of menopause status.